Werewolf Therapeutics to Participate at the Jefferies Global Healthcare Conference
Werewolf Therapeutics, an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics to stimulate the body's immune system for cancer treatment, announced its participation at the Jefferies Global Healthcare Conference.
Daniel J. Hicklin, Ph.D., President and CEO, and Randi Isaacs, M.D., Chief Medical Officer, will join a fireside chat at 1:00 PM ET on June 6, 2024. The conference will be held from June 4-6 in New York City.
A live webcast link for the event will be available on Werewolf's investor relations webpage, with an archived replay accessible for 90 days post-event.
- Werewolf's participation in a prominent industry conference increases visibility in the healthcare sector.
- The fireside chat with executive leadership might provide valuable insights to investors.
- A live webcast and 90-day replay ensure accessibility to a broad audience, potentially boosting investor confidence.
- The announcement lacks specific data or developments on clinical trials or financial performance.
- No immediate impact on revenue or stock valuation can be inferred from mere participation in the conference.
WATERTOWN, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced that Daniel J. Hicklin, Ph.D., President and Chief Executive Officer of Werewolf, and Randi Isaacs, M.D., Chief Medical Officer of Werewolf, will participate in a fireside chat at 1:00 PM ET on June 6 at the Jefferies Global Healthcare Conference, taking place June 4-6, 2024, in New York City, New York.
A live webcast link for the Jefferies Global Healthcare Conference event will be available at https://investors.werewolftx.com/news-and-events/events. An archived replay will be available for approximately 90 days following the event.
About Werewolf Therapeutics:
Werewolf Therapeutics, Inc., is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions. We are leveraging our proprietary PREDATOR™ platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Our INDUKINE™ molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. Our most advanced clinical stage product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2), and Interleukin-12 (IL-12) INDUKINE molecules, respectively, for the treatment of solid tumors. We expect to advance WTX-124 in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor and WTX-330 in multiple tumor types or Non-Hodgkin Lymphoma as a single agent.
Investor Contact:
Josh Rappaport
Precision AQ
212.362.1200
Josh.Rappaport@precisionaq.com
Amanda Sellers
VERGE Scientific Communications
301.332.5574
asellers@vergescientific.com
Company Contact:
Ellen Lubman
Chief Business Officer
Werewolf Therapeutics
elubman@werewolftx.com
FAQ
What event will Werewolf Therapeutics participate in June 2024?
When is the fireside chat with Werewolf Therapeutics' CEO and CMO?
Where can I watch the Werewolf Therapeutics fireside chat?
Who will represent Werewolf Therapeutics at the Jefferies Global Healthcare Conference?
What is the significance of Werewolf Therapeutics' participation in the Jefferies Global Healthcare Conference?
